Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Plinabulin (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ADVANCE
- Sponsors Nereus Pharmaceuticals
- 21 Feb 2017 Results published in the BeyondSpring Pharmaceuticals Media Release
- 21 Feb 2017 According to a BeyondSpring Pharmaceuticals media release, data from this trial has been selected for presentation at ASCO-SITC Clinical Immuno-Oncology Symposium.
- 19 Dec 2016 Results published in a BeyondSpring media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History